首页 > 最新文献

Terapevticheskii Arkhiv最新文献

英文 中文
[Prediction of the course of antibiotic-associated diarrhea caused by Clostridioides difficile based on clinical and laboratory characteristics of the disease]. [基于临床和实验室特征预测艰难梭菌引起的抗生素相关性腹泻的病程]。
IF 0.3 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-12-16 DOI: 10.26442/00403660.2024.11.203040
K D Ermolenko, T V Potapova, K V Silav, K V Zhdanov, D A Lioznov, D A Gusev

Background: The most severe complications of antibiotic use are clostridial infection (CDI) and pseudomembranous colitis (PMC). There is a need for further study of these conditions and identification of their triggers.

Aim: To identify risk factors for severe forms of antibiotic-associated diarrhea caused by Clostridioides difficile.

Materials and methods: A clinical and laboratory examination of 440 patients with CDI who were treated at Botkin Clinical Infectious Diseases Hospital was conducted. CDI was confirmed by detection of toxins A and B of C. difficile in feces using enzyme-linked immunosorbent assay and immunochromatography. Metronidazole (2 g/day, in patients without comorbid pathology) and vancomycin (0.5-2 g/day) were used as a starting drug for up to 14 days. Statistical processing of the obtained data was performed using the Statistica for Windows, v.10 (StatSoft, USA) program.

Results: CDI was confirmed by enzyme-linked immunosorbent assay in 202 (45.91%) patients, immunochromatography - in 149 (33.86%), endoscopically - in 203 (46.14%). CDI was most frequently recorded in 2 age groups of patients: 18-30 years old - in 137 (31.14%); over 60 years old - in 205 (46.59%). CDI was characterized by a combination of colitic and intoxication syndromes. In 43 (9.77%) patients the disease resulted in death. The diagnosis of PMС was established in 61 (13.86%) people. The risks of developing PMC when prescribing antibacterial drugs decreased in the following order: fluoroquinolones, cephalosporins, macrolides, penicillins, nitrofurans and chloramphenicol. Probiotic drugs reduced the risk of developing PMC (relative risk 0.5 [0.3; 0.7]; p=0.002).

Conclusion: PMC was characterized by a combination of diarrhea, intoxication and abdominal pain. The formation of PMC was preceded by courses of antibacterial drugs of the fluoroquinolone and cephalosporin groups, eradication therapy for Helicobacter infection, the use of high doses of glucocorticosteroids, as well as intestinal superinfection in patients with previous episodes of CDI.

背景:抗生素使用最严重的并发症是梭状菌感染(CDI)和假膜性结肠炎(PMC)。有必要进一步研究这些情况并确定其触发因素。目的:确定由艰难梭菌引起的严重形式抗生素相关性腹泻的危险因素。材料与方法:对在Botkin临床传染病医院治疗的440例CDI患者进行临床和实验室检查。采用酶联免疫吸附法和免疫层析法检测粪便中艰难梭菌毒素A和B,证实CDI。甲硝唑(2 g/天,无共病病理患者)和万古霉素(0.5-2 g/天)作为起始药物使用长达14天。使用Statistica for Windows, v.10对获得的数据进行统计处理(StatSoft, USA)程序。结果:酶联免疫吸附法确诊CDI 202例(45.91%),免疫层析法确诊149例(33.86%),内窥镜确诊203例(46.14%)。CDI最常见于2个年龄组的患者:18-30岁- 137例(31.14%);60岁以上——205年(46.59%)。CDI的特点是结肠炎和中毒综合征的结合。43例(9.77%)患者死亡。61例(13.86%)确诊为PMС。处方抗菌药物时发生PMC的风险依次为氟喹诺酮类、头孢菌素类、大环内酯类、青霉素类、硝基呋喃类和氯霉素类。益生菌药物降低发生PMC的风险(相对风险0.5 [0.3;0.7);p = 0.002)。结论:PMC以腹泻、中毒、腹痛为主要表现。PMC的形成是由氟喹诺酮类和头孢菌素组的抗菌药物疗程、幽门螺杆菌感染的根除治疗、高剂量糖皮质激素的使用以及既往CDI发作患者的肠道重复感染引起的。
{"title":"[Prediction of the course of antibiotic-associated diarrhea caused by <i>Clostridioides difficile</i> based on clinical and laboratory characteristics of the disease].","authors":"K D Ermolenko, T V Potapova, K V Silav, K V Zhdanov, D A Lioznov, D A Gusev","doi":"10.26442/00403660.2024.11.203040","DOIUrl":"https://doi.org/10.26442/00403660.2024.11.203040","url":null,"abstract":"<p><strong>Background: </strong>The most severe complications of antibiotic use are clostridial infection (CDI) and pseudomembranous colitis (PMC). There is a need for further study of these conditions and identification of their triggers.</p><p><strong>Aim: </strong>To identify risk factors for severe forms of antibiotic-associated diarrhea caused by <i>Clostridioides difficile</i>.</p><p><strong>Materials and methods: </strong>A clinical and laboratory examination of 440 patients with CDI who were treated at Botkin Clinical Infectious Diseases Hospital was conducted. CDI was confirmed by detection of toxins A and B of <i>C. difficile</i> in feces using enzyme-linked immunosorbent assay and immunochromatography. Metronidazole (2 g/day, in patients without comorbid pathology) and vancomycin (0.5-2 g/day) were used as a starting drug for up to 14 days. Statistical processing of the obtained data was performed using the Statistica for Windows, v.10 (StatSoft, USA) program.</p><p><strong>Results: </strong>CDI was confirmed by enzyme-linked immunosorbent assay in 202 (45.91%) patients, immunochromatography - in 149 (33.86%), endoscopically - in 203 (46.14%). CDI was most frequently recorded in 2 age groups of patients: 18-30 years old - in 137 (31.14%); over 60 years old - in 205 (46.59%). CDI was characterized by a combination of colitic and intoxication syndromes. In 43 (9.77%) patients the disease resulted in death. The diagnosis of PMС was established in 61 (13.86%) people. The risks of developing PMC when prescribing antibacterial drugs decreased in the following order: fluoroquinolones, cephalosporins, macrolides, penicillins, nitrofurans and chloramphenicol. Probiotic drugs reduced the risk of developing PMC (relative risk 0.5 [0.3; 0.7]; <i>p</i>=0.002).</p><p><strong>Conclusion: </strong>PMC was characterized by a combination of diarrhea, intoxication and abdominal pain. The formation of PMC was preceded by courses of antibacterial drugs of the fluoroquinolone and cephalosporin groups, eradication therapy for <i>Helicobacter</i> infection, the use of high doses of glucocorticosteroids, as well as intestinal superinfection in patients with previous episodes of CDI.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"96 11","pages":"1042-1048"},"PeriodicalIF":0.3,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142897903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Long-COVID, severe course, with congenital bronchiectasis, Williams-Campbell syndrome. Case report]. [长期covid,重症,先天性支气管扩张,威廉姆斯-坎贝尔综合征。病例报告)。
IF 0.3 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-12-16 DOI: 10.26442/00403660.2024.11.202997
S A Pribylov, T A Maslova, V S Pribylov, K O Leonidova, N N Pribylova, A P Kuts

We present a clinical observation of an 18-year-old female patient with congenital bronchiectasis combined with congenital cystic degeneration of the upper lobes of both lungs, Williams-Campbell syndrome, long-COVID, severe course. The patient was treated in infectious disease department (three times), with subsequent transfer to pulmonology department of Kursk Regional Multi-Purpose Clinical Hospital from 31.01.2023 to 02.05.2023. The patient was going to have lung transplantation, registered in Shumakov Federal Research Center of Transplantology and Artificial Organs earlier. The patient was transported by air ambulance escorted by the resuscitation team to the Shumakov Federal Research Center of Transplantology and Artificial Organs on 02.05.2023 with negative PCR COVID-19 test. The literature data on the frequency of association of these diseases, clinical features, criteria for diagnosis and treatment, indications for lung transplantation are presented.

我们报告1例18岁女性先天性支气管扩张合并双肺上叶先天性囊性变性患者的临床观察,Williams-Campbell综合征,长期covid,病程严重。患者于2023年1月31日至2023年5月2日在库尔斯克地区多功能临床医院感染性疾病科治疗(3次),随后转至肺病科。病人准备进行肺移植,早前在舒马科夫联邦移植和人工器官研究中心登记。患者于2023年5月2日由急救组护送空运至舒马科夫联邦移植与人工器官研究中心,PCR检测COVID-19阴性。文献资料的相关频率,这些疾病的临床特点,诊断和治疗标准,肺移植的适应症。
{"title":"[Long-COVID, severe course, with congenital bronchiectasis, Williams-Campbell syndrome. Case report].","authors":"S A Pribylov, T A Maslova, V S Pribylov, K O Leonidova, N N Pribylova, A P Kuts","doi":"10.26442/00403660.2024.11.202997","DOIUrl":"https://doi.org/10.26442/00403660.2024.11.202997","url":null,"abstract":"<p><p>We present a clinical observation of an 18-year-old female patient with congenital bronchiectasis combined with congenital cystic degeneration of the upper lobes of both lungs, Williams-Campbell syndrome, long-COVID, severe course. The patient was treated in infectious disease department (three times), with subsequent transfer to pulmonology department of Kursk Regional Multi-Purpose Clinical Hospital from 31.01.2023 to 02.05.2023. The patient was going to have lung transplantation, registered in Shumakov Federal Research Center of Transplantology and Artificial Organs earlier. The patient was transported by air ambulance escorted by the resuscitation team to the Shumakov Federal Research Center of Transplantology and Artificial Organs on 02.05.2023 with negative PCR COVID-19 test. The literature data on the frequency of association of these diseases, clinical features, criteria for diagnosis and treatment, indications for lung transplantation are presented.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"96 11","pages":"1089-1095"},"PeriodicalIF":0.3,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142897902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Combined echinococcosis of the lungs, heart and liver: clinic, diagnosis and treatment. Case report]. 肺、心、肝合并棘球蚴病:临床、诊断与治疗。病例报告)。
IF 0.3 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-12-16 DOI: 10.26442/00403660.2024.11.202998
E V Reznik, M D Iarovoi, S А Zavialova, S M Umakhanova, A S Grigorievskaya, O I Makolin, I V Semeniakin

Echinococcosis or hidatid disease is a parasitic illness which is caused by the most common pathogens Echinococcus granulosus, E. multilocularis and E. oligarthrus. When the agent gets into the organism, it penetrates the organ and forms a cyst. Cysts are located more often (75%) in the liver where they exist without any clinical manifestation. They can be located in other internal organs: lungs, the heart and others. The localization of cysts in several organs simultaneously is a very rare case. The article aims to demonstrate a patient who had a combined echinococcosis of the lungs, heart and liver.

棘球蚴病或包虫病是一种寄生虫病,由最常见的病原体颗粒棘球蚴、多形棘球蚴和少形棘球蚴引起。病原体进入机体后,会穿透器官并形成囊肿。囊肿通常(75%)位于肝脏,在那里没有任何临床表现。囊肿也可能位于其他内脏器官:肺、心脏等。囊肿同时位于多个器官的情况非常罕见。本文旨在展示一名同时患有肺、心脏和肝脏棘球蚴病的患者。
{"title":"[Combined echinococcosis of the lungs, heart and liver: clinic, diagnosis and treatment. Case report].","authors":"E V Reznik, M D Iarovoi, S А Zavialova, S M Umakhanova, A S Grigorievskaya, O I Makolin, I V Semeniakin","doi":"10.26442/00403660.2024.11.202998","DOIUrl":"10.26442/00403660.2024.11.202998","url":null,"abstract":"<p><p>Echinococcosis or hidatid disease is a parasitic illness which is caused by the most common pathogens <i>Echinococcus granulosus</i>, <i>E. multilocularis </i>and <i>E. oligarthrus</i>. When the agent gets into the organism, it penetrates the organ and forms a cyst. Cysts are located more often (75%) in the liver where they exist without any clinical manifestation. They can be located in other internal organs: lungs, the heart and others. The localization of cysts in several organs simultaneously is a very rare case. The article aims to demonstrate a patient who had a combined echinococcosis of the lungs, heart and liver.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"96 11","pages":"1097-1103"},"PeriodicalIF":0.3,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142897917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Evaluation of the results of magnetic resonance imaging of the brain for cognitive impairment in patients with heart failure: A review]. [心力衰竭患者认知障碍的脑磁共振成像结果评估:综述]。
IF 0.3 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-10 DOI: 10.26442/00403660.2024.09.202853
M A Shariya, D V Ustyuzhanin, I V Zhirov, Y F Osmolovskaya, S N Tereshchenko

Cognitive impairment is a very common comorbidity in patients with heart failure (HF). Patients with HF show signs of memory decline, difficulty concentrating, and attention deficits. Cognitive dysfunction in HF is associated with a poor prognosis. However, the diagnosis of cognitive impairment in heart failure has received insufficient attention in routine clinical practice. Neuropsychological screening tests are available to screen for cognitive impairment, but they are used infrequently. Therefore, it is of practical interest to search for magnetic resonance equivalents of cognitive disorders. The use of magnetic resonance imaging as a tool for identifying and quantifying neural correlates of cognitive functions is discussed.

认知障碍是心力衰竭(HF)患者非常常见的合并症。心力衰竭患者会出现记忆力下降、注意力难以集中、注意力不集中等症状。心力衰竭患者的认知功能障碍与预后不良有关。然而,在常规临床实践中,心力衰竭认知功能障碍的诊断并未得到足够重视。神经心理学筛查测试可用于筛查认知功能障碍,但使用频率不高。因此,寻找认知障碍的磁共振对应物具有实际意义。本文讨论了如何将磁共振成像作为一种工具,用于识别和量化认知功能的神经相关性。
{"title":"[Evaluation of the results of magnetic resonance imaging of the brain for cognitive impairment in patients with heart failure: A review].","authors":"M A Shariya, D V Ustyuzhanin, I V Zhirov, Y F Osmolovskaya, S N Tereshchenko","doi":"10.26442/00403660.2024.09.202853","DOIUrl":"https://doi.org/10.26442/00403660.2024.09.202853","url":null,"abstract":"<p><p>Cognitive impairment is a very common comorbidity in patients with heart failure (HF). Patients with HF show signs of memory decline, difficulty concentrating, and attention deficits. Cognitive dysfunction in HF is associated with a poor prognosis. However, the diagnosis of cognitive impairment in heart failure has received insufficient attention in routine clinical practice. Neuropsychological screening tests are available to screen for cognitive impairment, but they are used infrequently. Therefore, it is of practical interest to search for magnetic resonance equivalents of cognitive disorders. The use of magnetic resonance imaging as a tool for identifying and quantifying neural correlates of cognitive functions is discussed.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"96 9","pages":"909-913"},"PeriodicalIF":0.3,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142523180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Polymorphism of RAAS genes in patients with COVID-19: comparison with frequency in population and relationship with severity of course]. [COVID-19患者RAAS基因的多态性:与人群频率的比较及与病程严重程度的关系]。
IF 0.3 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-10 DOI: 10.26442/00403660.2024.09.202849
A E Bragina, Y N Rodionova, E S Ogibenina, A S Fomin, V I Podzolkov

Aim: Evaluation of genes polymorphisms frequencies of angiotensinogen (AGT), angiotensin converting enzyme type 1 (ACE1) and angiotensin II receptors type 1 (AGTR1) and type 2 (AGTR2) in patients admitted with coronavirus disease (COVID-19) and its association the severity of severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2).

Materials and methods: The study included 100 patients admitted to the hospital with a laboratory-confirmed diagnosis of COVID-19. All patients were identified with alleles and genotypes of polymorphic markers rs4762 of the AGT gene, rs1799752 of the ACE1 gene, rs5186 of the AGTR1 gene and rs1403543 of the AGTR2 gene. The frequencies of each polymorphisms were compared with population. Statistical processing was performed using the Statistica 8.0 software package.

Results: In evaluated cohort there was higher frequency of D-allele ACE1 rs1799752 compared to population. Depending on the availability of criteria for the severity of coronavirus infection, 44 (44%) patients were diagnosed with severe, 56 (56%) with moderate course. The groups did not significantly differ in age, gender, cardiovascular risk factors and comorbid pathology. In the groups with severe and moderate course, the same distribution of genotypes and alleles of AGT rs4762, AGTR2 rs1403543 and ACE1 rs1799752 was revealed. For the I/D alleles of the ACE1 rs1799752 gene, a significant deviation from the papulation was found in both the group of severe and moderate COVID-19. In the group with a severe course of the disease, a higher frequency of the mutant C-allele of the AGTR1 rs5186 gene was detected. In the same group, a deviation in the frequency ratio of A and C of the AGTR1 rs5186 alleles from Hardy-Weinberg Equilibrium was found. When calculating the risk of severe COVID-19 in the presence of the C-allele compared with the A-allele, an odds ratio 2.092 (95% confidence interval 1.066-4.108) was obtained.

Conclusion: The data obtained suggest that the genes polymorphisms of the components of renin-angiotensin-aldosterone system, namely D-allele of ACE1 rs1799752 and C-allele of AGTR1 rs5186, may make it possible to identify groups of patients predisposed to the development of more severe COVID-19.

目的:评估冠状病毒病(COVID-19)患者血管紧张素原(AGT)、血管紧张素转换酶1型(ACE1)、血管紧张素II受体1型(AGTR1)和2型(AGTR2)的基因多态性频率及其与严重急性呼吸系统综合征相关冠状病毒-2(SARS-CoV-2)严重程度的关系:研究对象包括 100 名经实验室确诊为 COVID-19 的住院患者。对所有患者的 AGT 基因 rs4762、ACE1 基因 rs1799752、AGTR1 基因 rs5186 和 AGTR2 基因 rs1403543 多态性标记的等位基因和基因型进行了鉴定。各多态性的频率与人群进行了比较。统计处理使用 Statistica 8.0 软件包进行:结果:在接受评估的队列中,D-等位基因 ACE1 rs1799752 的频率高于人群。根据冠状病毒感染严重程度的标准,44(44%)名患者被诊断为重度感染,56(56%)名患者被诊断为中度感染。两组患者在年龄、性别、心血管风险因素和合并病症方面没有明显差异。在重度和中度病程组中,AGT rs4762、AGTR2 rs1403543 和 ACE1 rs1799752 的基因型和等位基因分布相同。至于 ACE1 rs1799752 基因的 I/D 等位基因,在重度和中度 COVID-19 组中都发现与乳头状明显偏离。在重度病程组中,检测到 AGTR1 rs5186 基因的突变 C 等位基因频率较高。在同一组中,AGTR1 rs5186 等位基因的 A 和 C 的频率比偏离了哈代-温伯格平衡(Hardy-Weinberg Equilibrium)。在计算存在 C 等位基因与 A 等位基因时罹患严重 COVID-19 的风险时,得出的几率比为 2.092(95% 置信区间为 1.066-4.108):所获数据表明,肾素-血管紧张素-醛固酮系统成分的基因多态性,即 ACE1 的 D-等位基因 rs1799752 和 AGTR1 的 C-等位基因 rs5186,可用于识别易患更严重 COVID-19 的患者群体。
{"title":"[Polymorphism of RAAS genes in patients with COVID-19: comparison with frequency in population and relationship with severity of course].","authors":"A E Bragina, Y N Rodionova, E S Ogibenina, A S Fomin, V I Podzolkov","doi":"10.26442/00403660.2024.09.202849","DOIUrl":"10.26442/00403660.2024.09.202849","url":null,"abstract":"<p><strong>Aim: </strong>Evaluation of genes polymorphisms frequencies of angiotensinogen (AGT), angiotensin converting enzyme type 1 (ACE1) and angiotensin II receptors type 1 (AGTR1) and type 2 (AGTR2) in patients admitted with coronavirus disease (COVID-19) and its association the severity of severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2).</p><p><strong>Materials and methods: </strong>The study included 100 patients admitted to the hospital with a laboratory-confirmed diagnosis of COVID-19. All patients were identified with alleles and genotypes of polymorphic markers rs4762 of the AGT gene, rs1799752 of the ACE1 gene, rs5186 of the AGTR1 gene and rs1403543 of the AGTR2 gene. The frequencies of each polymorphisms were compared with population. Statistical processing was performed using the Statistica 8.0 software package.</p><p><strong>Results: </strong>In evaluated cohort there was higher frequency of D-allele ACE1 rs1799752 compared to population. Depending on the availability of criteria for the severity of coronavirus infection, 44 (44%) patients were diagnosed with severe, 56 (56%) with moderate course. The groups did not significantly differ in age, gender, cardiovascular risk factors and comorbid pathology. In the groups with severe and moderate course, the same distribution of genotypes and alleles of AGT rs4762, AGTR2 rs1403543 and ACE1 rs1799752 was revealed. For the I/D alleles of the ACE1 rs1799752 gene, a significant deviation from the papulation was found in both the group of severe and moderate COVID-19. In the group with a severe course of the disease, a higher frequency of the mutant C-allele of the AGTR1 rs5186 gene was detected. In the same group, a deviation in the frequency ratio of A and C of the AGTR1 rs5186 alleles from Hardy-Weinberg Equilibrium was found. When calculating the risk of severe COVID-19 in the presence of the C-allele compared with the A-allele, an odds ratio 2.092 (95% confidence interval 1.066-4.108) was obtained.</p><p><strong>Conclusion: </strong>The data obtained suggest that the genes polymorphisms of the components of renin-angiotensin-aldosterone system, namely D-allele of ACE1 rs1799752 and C-allele of AGTR1 rs5186, may make it possible to identify groups of patients predisposed to the development of more severe COVID-19.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"96 9","pages":"872-878"},"PeriodicalIF":0.3,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142523184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Biomarkers in acute coronary syndromes: from the origins to the present]. [急性冠状动脉综合征的生物标志物:从起源到现在]。
IF 0.3 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-10 DOI: 10.26442/00403660.2024.09.202854
E A Okisheva, O I Trushina

Acute coronary syndrome remains the leading cause of death in both patients with coronary artery disease and patients with other diseases (such as diabetes mellitus, chronic kidney disease, inflammatory diseases of various etiologies, and others). Early diagnosis of cardiomyocyte damage and necrosis opens up wide opportunities to improve the prognosis of patients with atherosclerotic lesions of the coronary arteries, and also makes it possible to discharge patients without acute cardiovascular pathology from intensive care units with a high degree of probability. The article discusses the evolution of the research and introduction into broad clinical practice of markers of myocardial damage and necrosis, which have largely improved modern clinical practice.

急性冠状动脉综合征仍然是冠状动脉疾病患者和其他疾病(如糖尿病、慢性肾病、各种病因的炎症性疾病等)患者的主要死因。对心肌细胞损伤和坏死的早期诊断为改善冠状动脉粥样硬化病变患者的预后提供了广阔的机会,也使没有急性心血管病变的患者从重症监护室出院的可能性大大提高。文章讨论了心肌损伤和坏死标志物的研究演变和引入广泛临床实践的情况,这些标志物在很大程度上改善了现代临床实践。
{"title":"[Biomarkers in acute coronary syndromes: from the origins to the present].","authors":"E A Okisheva, O I Trushina","doi":"10.26442/00403660.2024.09.202854","DOIUrl":"10.26442/00403660.2024.09.202854","url":null,"abstract":"<p><p>Acute coronary syndrome remains the leading cause of death in both patients with coronary artery disease and patients with other diseases (such as diabetes mellitus, chronic kidney disease, inflammatory diseases of various etiologies, and others). Early diagnosis of cardiomyocyte damage and necrosis opens up wide opportunities to improve the prognosis of patients with atherosclerotic lesions of the coronary arteries, and also makes it possible to discharge patients without acute cardiovascular pathology from intensive care units with a high degree of probability. The article discusses the evolution of the research and introduction into broad clinical practice of markers of myocardial damage and necrosis, which have largely improved modern clinical practice.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"96 9","pages":"914-918"},"PeriodicalIF":0.3,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142523179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Metabolic disorders in patients with chronic thromboembolic pulmonary hypertension]. [慢性血栓栓塞性肺动脉高压患者的代谢紊乱]。
IF 0.3 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-10 DOI: 10.26442/00403660.2024.09.202850
S Y Yarovoy, N M Danilov, G V Shchelkova, E O Dinevich, A A Mitrofanova, I E Chazova

Aim: To analyze the relationship between metabolic disorders and obesity with hemodynamic parameters and the severity of the condition of patients with chronic thromboembolic pulmonary hypertension (CTEPH) based on the POLET register.

Materials and methods: The study included patients with CTEPH from the POLET register. Data from medical history, lipid profile, glycemia, uric acid level, weight, height, functional class (FC), distance in the 6-minute walk test (6MWT), echocardiography, and right heart catheterization were used for analysis.

Results: The study included 84 patients 60±14 years old, including 45 men. The majority of patients had FC III - 51 (65%), which corresponded to 6MWT - 338±113 m. Nineteen (23%) people had experience in taking PAH specific therapy, 37 (46%) had cardiovascular comorbidity. In the general group, the body mass index (BMI) was 25.7±4.5 kg/m2, and normal glycemia, lipid profile, and uric acid levels were also determined. mPAP was 51±12 mmHg, RA area was 25.5 (20; 30) cm2. Correlations were identified between: RA area and the level of total cholesterol (r=0.60; p<0.01), triglycerides (r=-0.24; p<0.001), LDL cholesterol (r=0.75; p=0.04), uric acid (r=0.75; p=0.03); total cholesterol and 6MWT (r=0.44; p=0.04). Analysis of metabolic disorders, FC and comorbidity revealed differences between FC III and IV groups in the level of HDL cholesterol (p=0.02) and triglycerides (p<0.01).

Conclusion: The POLET registry includes mainly older patients. Severe FC (87% - III and IV) may be a result of the older age and the presence of concomitant pathology in almost half of the patients. The discovered relationships between the area of RA and FC with lipid and purine metabolism were discovered for the first time, however, they correspond to the direction of the world scientific researches, are important due to the use of these indicators in the scale for calculating the risk of death in patients with PAH and require further development.

目的:根据 POLET 登记资料,分析代谢紊乱和肥胖与慢性血栓栓塞性肺动脉高压(CTEPH)患者血液动力学参数和病情严重程度之间的关系:研究对象包括 POLET 登记的 CTEPH 患者。分析数据包括病史、血脂、血糖、尿酸水平、体重、身高、功能分级(FC)、6 分钟步行测试(6MWT)距离、超声心动图和右心导管检查:研究共纳入 84 名年龄为 60±14 岁的患者,其中男性 45 人。19人(23%)有接受 PAH 特定治疗的经历,37人(46%)有心血管合并症。普通组的体重指数(BMI)为(25.7±4.5)kg/m2,血糖、血脂和尿酸水平正常。结果表明RA 面积与总胆固醇水平 (r=0.60; ppp=0.04) 和尿酸水平 (r=0.75; p=0.03);总胆固醇与 6MWT (r=0.44; p=0.04)。对代谢紊乱、FC 和合并症的分析表明,FC III 组和 IV 组在高密度脂蛋白胆固醇(P=0.02)和甘油三酯(P=0.04)水平上存在差异:POLET登记册主要包括老年患者。严重的 FC(87% - III 和 IV)可能是由于年龄较大以及近一半的患者伴有病变。首次发现了 RA 和 FC 面积与脂质和嘌呤代谢之间的关系,但这些关系符合世界科学研究的方向,由于在计算 PAH 患者死亡风险的量表中使用了这些指标,因此这些关系非常重要,需要进一步发展。
{"title":"[Metabolic disorders in patients with chronic thromboembolic pulmonary hypertension].","authors":"S Y Yarovoy, N M Danilov, G V Shchelkova, E O Dinevich, A A Mitrofanova, I E Chazova","doi":"10.26442/00403660.2024.09.202850","DOIUrl":"https://doi.org/10.26442/00403660.2024.09.202850","url":null,"abstract":"<p><strong>Aim: </strong>To analyze the relationship between metabolic disorders and obesity with hemodynamic parameters and the severity of the condition of patients with chronic thromboembolic pulmonary hypertension (CTEPH) based on the POLET register.</p><p><strong>Materials and methods: </strong>The study included patients with CTEPH from the POLET register. Data from medical history, lipid profile, glycemia, uric acid level, weight, height, functional class (FC), distance in the 6-minute walk test (6MWT), echocardiography, and right heart catheterization were used for analysis.</p><p><strong>Results: </strong>The study included 84 patients 60±14 years old, including 45 men. The majority of patients had FC III - 51 (65%), which corresponded to 6MWT - 338±113 m. Nineteen (23%) people had experience in taking PAH specific therapy, 37 (46%) had cardiovascular comorbidity. In the general group, the body mass index (BMI) was 25.7±4.5 kg/m<sup>2</sup>, and normal glycemia, lipid profile, and uric acid levels were also determined. mPAP was 51±12 mmHg, RA area was 25.5 (20; 30) cm<sup>2</sup>. Correlations were identified between: RA area and the level of total cholesterol (r=0.60; <i>p</i><0.01), triglycerides (r=-0.24; <i>p</i><0.001), LDL cholesterol (r=0.75; <i>p</i><i>=</i>0.04), uric acid (r=0.75; <i>p</i>=0.03); total cholesterol and 6MWT (r=0.44; <i>p</i>=0.04). Analysis of metabolic disorders, FC and comorbidity revealed differences between FC III and IV groups in the level of HDL cholesterol (<i>p</i>=0.02) and triglycerides (<i>p</i><0.01).</p><p><strong>Conclusion: </strong>The POLET registry includes mainly older patients. Severe FC (87% - III and IV) may be a result of the older age and the presence of concomitant pathology in almost half of the patients. The discovered relationships between the area of RA and FC with lipid and purine metabolism were discovered for the first time, however, they correspond to the direction of the world scientific researches, are important due to the use of these indicators in the scale for calculating the risk of death in patients with PAH and require further development.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"96 9","pages":"879-884"},"PeriodicalIF":0.3,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142523182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[A clinical case of reverse left ventricular remodeling in patient with pathogenic TTN mutation. Case report]. [致病性 TTN 突变患者左心室反向重塑的临床病例。病例报告]。
IF 0.3 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-10 DOI: 10.26442/00403660.2024.09.202852
S N Nasonova, A N Meshkov, I V Zhirov, Y F Osmolovskaya, A A Shoshina, A V Gagloev, I H Dzhumaniiazova, E A Zelenova, V V Erema, M S Gusakova, M V Ivanov, M V Terekhov, D A Kashtanova, A I Nekrasova, S I Mitrofanov, A S Shingaliev, V S Yudin, A A Keskinov, N V Gomyranova, U V Chubykina, M V Ezhov, S N Tereshchenko, S M Yudin, S A Boytsov

Dilated cardiomyopathy (DCM) is a leading cause of heart failure, sudden cardiac death, and heart transplantation in young patients. The causes of DCM are varied and include genetic factors and metabolic, infectious, toxic and others factors. Today it is known that germline mutations in more than 98 genes can be associated with the occurrence of DCM. However, the penetrance of these genes often depends on a combination of factors, including modifiable ones, i.e. those that change under the influence of the environment. About 20-25% of genetically determined forms of DCM are due to mutations in the titin gene (TTN). Titin is the largest protein in the body, which is an important component of the sarcomer. Although titin is the largest protein in the human body, its role in the physiology of heart and disease is not yet fully understood. However, a mutation in the TTN gene may later represent a potential therapeutic target for genetic and acquired cardiomyopathy. Thus, the analysis of clinical cases of cardiomyopathy in patients with identified mutations in the TTN gene is of great scientific interest. The article presents a clinical case of manifestation of DCM in patient with a revealed pathogenic variant of mutation in the gene TTN and reverse left ventricular remodeling of the against the background of optimal therapy of heart failure in a subsequent outpatient observation.

扩张型心肌病(DCM)是导致年轻患者心力衰竭、心脏性猝死和心脏移植的主要原因。DCM 的病因多种多样,包括遗传因素、代谢因素、感染因素、毒性因素和其他因素。目前已知有超过 98 个基因的种系突变与 DCM 的发生有关。然而,这些基因的穿透性往往取决于多种因素,包括可改变的因素,即在环境影响下发生变化的因素。在由基因决定的 DCM 中,约有 20-25% 是由于 titin 基因(TTN)的突变造成的。titin 是人体内最大的蛋白质,是肌纤维的重要组成部分。虽然 titin 是人体内最大的蛋白质,但它在心脏生理和疾病中的作用尚未完全明了。然而,TTN 基因的突变日后可能成为遗传性和获得性心肌病的潜在治疗靶点。因此,对已发现 TTN 基因突变的心肌病患者的临床病例进行分析具有重要的科学意义。本文介绍了一例临床病例,该病例患者的 DCM 表现为 TTN 基因突变的致病变异,在随后的门诊观察中,在心力衰竭最佳治疗的背景下,左心室反向重塑。
{"title":"[A clinical case of reverse left ventricular remodeling in patient with pathogenic TTN mutation. Case report].","authors":"S N Nasonova, A N Meshkov, I V Zhirov, Y F Osmolovskaya, A A Shoshina, A V Gagloev, I H Dzhumaniiazova, E A Zelenova, V V Erema, M S Gusakova, M V Ivanov, M V Terekhov, D A Kashtanova, A I Nekrasova, S I Mitrofanov, A S Shingaliev, V S Yudin, A A Keskinov, N V Gomyranova, U V Chubykina, M V Ezhov, S N Tereshchenko, S M Yudin, S A Boytsov","doi":"10.26442/00403660.2024.09.202852","DOIUrl":"10.26442/00403660.2024.09.202852","url":null,"abstract":"<p><p>Dilated cardiomyopathy (DCM) is a leading cause of heart failure, sudden cardiac death, and heart transplantation in young patients. The causes of DCM are varied and include genetic factors and metabolic, infectious, toxic and others factors. Today it is known that germline mutations in more than 98 genes can be associated with the occurrence of DCM. However, the penetrance of these genes often depends on a combination of factors, including modifiable ones, i.e. those that change under the influence of the environment. About 20-25% of genetically determined forms of DCM are due to mutations in the titin gene (<i>TTN</i>). Titin is the largest protein in the body, which is an important component of the sarcomer. Although titin is the largest protein in the human body, its role in the physiology of heart and disease is not yet fully understood. However, a mutation in the <i>TTN</i> gene may later represent a potential therapeutic target for genetic and acquired cardiomyopathy. Thus, the analysis of clinical cases of cardiomyopathy in patients with identified mutations in the <i>TTN</i> gene is of great scientific interest. The article presents a clinical case of manifestation of DCM in patient with a revealed pathogenic variant of mutation in the gene <i>TTN</i> and reverse left ventricular remodeling of the against the background of optimal therapy of heart failure in a subsequent outpatient observation.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"96 9","pages":"901-908"},"PeriodicalIF":0.3,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142523177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Patient selection for left ventricular assist device implantation. The main problems]. [左心室辅助装置植入术的患者选择。主要问题]。
IF 0.3 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-10 DOI: 10.26442/00403660.2024.09.202851
O Y Narusov, J A Shahramanova, V A Amanatova, A V Sychev, Y F Osmolovskaya, K G Ganaev, A A Shiryaev, I A Merkulova, D V Pevzner, M I Makeev, M A Saidova, F N Paleev, R S Akchurin, S N Tereshchenko, S A Boytsov

Aim: To analyze the experience of Chazov National Medical Research Center of Cardiology in patient selection for left ventricular assist device (LVAD) implantation.

Materials and methods: 901 patients, whose documents were sent to Chazov National Medical Research Center of Cardiology from regional medical and prophylactic institutions, were screened as selection for LVAD implantation. Firstly, all patients underwent transthoracic echocardiography performed according to the extended protocol with a comprehensive assessment of the left and right ventricle size and function. Patients who underwent the screening procedure underwent further examination including both laboratory and instrumental diagnostic methods. In addition, the polyclinic database of patients diagnosed with chronic heart failure (CHF) and dilated cardiomyopathy was also analyzed.

Results: Among 901 screened patients 7.9% were suitable candidates for LVAD implantation and only 23 (2.6%) patients underwent surgery. Among those not eligible for surgery: 208 (29%) patients were not on optimal medical therapy, 15% of patients had indications for other surgical treatment of CHF, 12% of patients had severe right ventricular failure, 9.8% had severe comorbidities, 6.8% of patients refused surgery.

Conclusions: The main problems of selection for LVAD implantation were: low awareness of doctors about the introduction of new treatment methods, poor quality of transthoracic echocardiography, a large percentage of patients not receiving basic therapy for CHF, untimely referral of patients for other types of surgical treatment.

目的:分析查佐夫国立心脏病学医学研究中心在选择左心室辅助装置(LVAD)植入患者方面的经验。材料与方法:从地区医疗和预防机构向查佐夫国立心脏病学医学研究中心递交文件的 901 名患者被筛选为左心室辅助装置植入患者。首先,所有患者均按照扩展方案接受经胸超声心动图检查,全面评估左心室和右心室的大小和功能。接受筛查的患者还需接受进一步检查,包括实验室和仪器诊断方法。此外,还对诊断为慢性心力衰竭(CHF)和扩张型心肌病患者的综合医院数据库进行了分析:在 901 名经过筛查的患者中,有 7.9% 的患者适合植入 LVAD,只有 23 名(2.6%)患者接受了手术。在不符合手术条件的患者中,208 名患者(29%)没有接受最佳的药物治疗,15%的患者有其他手术治疗 CHF 的指征,12%的患者有严重的右心室衰竭,9.8%的患者有严重的合并症,6.8%的患者拒绝手术:选择 LVAD 植入术的主要问题是:医生对引进新治疗方法的认识不足、经胸超声心动图检查质量差、很大比例的患者未接受 CHF 基础治疗、患者未及时转诊接受其他类型的外科治疗。
{"title":"[Patient selection for left ventricular assist device implantation. The main problems].","authors":"O Y Narusov, J A Shahramanova, V A Amanatova, A V Sychev, Y F Osmolovskaya, K G Ganaev, A A Shiryaev, I A Merkulova, D V Pevzner, M I Makeev, M A Saidova, F N Paleev, R S Akchurin, S N Tereshchenko, S A Boytsov","doi":"10.26442/00403660.2024.09.202851","DOIUrl":"https://doi.org/10.26442/00403660.2024.09.202851","url":null,"abstract":"<p><strong>Aim: </strong>To analyze the experience of Chazov National Medical Research Center of Cardiology in patient selection for left ventricular assist device (LVAD) implantation.</p><p><strong>Materials and methods: </strong>901 patients, whose documents were sent to Chazov National Medical Research Center of Cardiology from regional medical and prophylactic institutions, were screened as selection for LVAD implantation. Firstly, all patients underwent transthoracic echocardiography performed according to the extended protocol with a comprehensive assessment of the left and right ventricle size and function. Patients who underwent the screening procedure underwent further examination including both laboratory and instrumental diagnostic methods. In addition, the polyclinic database of patients diagnosed with chronic heart failure (CHF) and dilated cardiomyopathy was also analyzed.</p><p><strong>Results: </strong>Among 901 screened patients 7.9% were suitable candidates for LVAD implantation and only 23 (2.6%) patients underwent surgery. Among those not eligible for surgery: 208 (29%) patients were not on optimal medical therapy, 15% of patients had indications for other surgical treatment of CHF, 12% of patients had severe right ventricular failure, 9.8% had severe comorbidities, 6.8% of patients refused surgery.</p><p><strong>Conclusions: </strong>The main problems of selection for LVAD implantation were: low awareness of doctors about the introduction of new treatment methods, poor quality of transthoracic echocardiography, a large percentage of patients not receiving basic therapy for CHF, untimely referral of patients for other types of surgical treatment.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"96 9","pages":"885-891"},"PeriodicalIF":0.3,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142523183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Antihypertensive therapy in patients with arterial hypertension and concomitant diseases in real clinical practice (according to the National Registry of Arterial Hypertension, 2019-2022)]. [真实临床实践中动脉高血压和伴随疾病患者的抗高血压治疗(根据国家动脉高血压登记处,2019-2022 年)】。]
IF 0.3 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-10 DOI: 10.26442/00403660.2024.09.202848
A V Aksenova, E V Oschepkova, I E Chazova
<p><strong>Background: </strong>Arterial hypertension (AH) remains the leading risk factor associated with cardiovascular diseases (CVDs), cerebrovascular disease and chronic kidney disease. About 70% of patients with AH who are on monotherapy cannot achieve blood pressure (BP) targets, and therefore all quidelines for the management of AH have recently recommended prescribing combination therapy (PCT). In real clinical practice (RCP), there remains significant uncertainty in the effectiveness and rationality of therapy, despite the wide availability of antihypertensive drugs (AHD) and the presence of recommendations for a stepwise approach to prescribing combinations of specific groups of AHD in different clinical situations.</p><p><strong>Aim: </strong>Analyze the real ongoing antihypertensive therapy, including the PCT; international nonproprietary names of drugs and their dosages in RCP; compliance of therapy with clinical recommendations; changing trends in the PCT.</p><p><strong>Materials and methods: </strong>An analysis was carried out of the data from the register of AH, the compliance of treatment in different clinical groups of patients and the achievement of BP and low-density lipoprotein cholesterol targets in the sample of 2019-2022 (<i>n</i>=5012). The prescription of AHD and achievement of targets values were assessed in accordance with current clinical guidelines for the management of AH and hypercholesterolemia. Data from 2010 (<i>n</i>=7782) and 2020 (<i>n</i>=3061) were analyzed to assess the dynamics of prescription of monotherapy and PCT.</p><p><strong>Results: </strong>The greatest increase in the number of AHD was observed in patients with hypertension in combination with coronary heart disease, heart failure, and atrial fibrillation. In a small group of patients with hypertension without other CVDs, the recommended combinations of AHD were not prescribed; preference was given to angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and β-adrenoblocker (β-AB). PCT mainly differed from the recommended combinations by the wider use of drugs from the β-AB group. The PCT of recommended drugs was highest in patients with hypertension and coronary artery disease - more than 90%, hypertension and heart failure in 56.2%, hypertension and atrial fibrillation - 33.3%, hypertension and chronic kidney desease - 19.6%. Achievement of BP and low-density lipoprotein cholesterol targets was insufficient in all analyzed groups. Among the international nonproprietary names of drugs, the most frequently prescribed are the following: bisoprolol, metoprolol, lisinopril, perindopril, losartan, spironolactone, amlodipine, torasemide, indapamide, hypochlorothiazide, moxonidine. The prescribed daily dosages were closer to the initial recommended ones. By 2020, the prescription of PCT with β-AB and a more uniform prescription of various combinations will come to the fore, while PCT in 2010 is characterized by the presence of one
背景:动脉高血压(AH)仍然是与心血管疾病(CVD)、脑血管疾病和慢性肾脏疾病相关的主要风险因素。在接受单一疗法的动脉高血压患者中,约有 70% 的患者无法达到血压(BP)目标,因此,最近所有动脉高血压管理指南都建议处方联合疗法(PCT)。在实际临床实践(RCP)中,尽管抗高血压药物(AHD)种类繁多,而且有建议指出在不同临床情况下应采取循序渐进的方式对特定类别的抗高血压药物进行组合处方,但治疗的有效性和合理性仍存在很大的不确定性。目的:分析实际正在进行的抗高血压治疗,包括 PCT;RCP 中药物的国际非专利名称及其剂量;治疗是否符合临床建议;PCT 的变化趋势:对 AH 登记数据、不同临床组患者的治疗依从性以及 2019-2022 年样本(n=5012)中血压和低密度脂蛋白胆固醇目标的实现情况进行了分析。AHD的处方和目标值的实现情况是根据目前AH和高胆固醇血症管理的临床指南进行评估的。对2010年(n=7782)和2020年(n=3061)的数据进行了分析,以评估单一疗法和PCT处方的动态变化:结果显示:高血压合并冠心病、心力衰竭和心房颤动患者的 AHD 数量增幅最大。在一小部分无其他心血管疾病的高血压患者中,没有处方推荐的抗高血压药物组合,而是优先选择了血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂和β-肾上腺素受体阻滞剂(β-AB)。PCT 与推荐组合的主要区别在于更广泛地使用了 β-AB 组药物。高血压合并冠状动脉疾病患者的 PCT 值最高,超过 90%;高血压合并心力衰竭患者的 PCT 值最高,达到 56.2%;高血压合并心房颤动患者的 PCT 值最高,达到 33.3%;高血压合并慢性肾病患者的 PCT 值最高,达到 19.6%。在所有被分析的群体中,血压和低密度脂蛋白胆固醇的目标都没有达到。在国际非专有药名中,最常用的处方药如下:比索洛尔、美托洛尔、利辛普利、培哚普利、洛沙坦、螺内酯、氨氯地平、托拉塞米、吲哒帕胺、次氯噻嗪、莫索尼定。处方的每日剂量更接近最初推荐的剂量。到 2020 年,PCT 与 β-AB 的处方和各种组合的处方将更加统一,而 2010 年的 PCT 处方特点是存在一到两个领先组合:结论:所描述的 AHD 处方特点部分再现了 AH 治疗的临床建议。RCP中提供的治疗差异可能与试图加强对合并其他心血管疾病的高血压患者的治疗有关。同时,对处方药组合和剂量的分析表明,存在进一步升级治疗的广泛机会。所提供的数据可以让人们深入了解目前 RCP 患者的降压治疗处方模式,并为优化不同类别高血压患者的治疗奠定基础。
{"title":"[Antihypertensive therapy in patients with arterial hypertension and concomitant diseases in real clinical practice (according to the National Registry of Arterial Hypertension, 2019-2022)].","authors":"A V Aksenova, E V Oschepkova, I E Chazova","doi":"10.26442/00403660.2024.09.202848","DOIUrl":"https://doi.org/10.26442/00403660.2024.09.202848","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Arterial hypertension (AH) remains the leading risk factor associated with cardiovascular diseases (CVDs), cerebrovascular disease and chronic kidney disease. About 70% of patients with AH who are on monotherapy cannot achieve blood pressure (BP) targets, and therefore all quidelines for the management of AH have recently recommended prescribing combination therapy (PCT). In real clinical practice (RCP), there remains significant uncertainty in the effectiveness and rationality of therapy, despite the wide availability of antihypertensive drugs (AHD) and the presence of recommendations for a stepwise approach to prescribing combinations of specific groups of AHD in different clinical situations.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Aim: &lt;/strong&gt;Analyze the real ongoing antihypertensive therapy, including the PCT; international nonproprietary names of drugs and their dosages in RCP; compliance of therapy with clinical recommendations; changing trends in the PCT.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Materials and methods: &lt;/strong&gt;An analysis was carried out of the data from the register of AH, the compliance of treatment in different clinical groups of patients and the achievement of BP and low-density lipoprotein cholesterol targets in the sample of 2019-2022 (&lt;i&gt;n&lt;/i&gt;=5012). The prescription of AHD and achievement of targets values were assessed in accordance with current clinical guidelines for the management of AH and hypercholesterolemia. Data from 2010 (&lt;i&gt;n&lt;/i&gt;=7782) and 2020 (&lt;i&gt;n&lt;/i&gt;=3061) were analyzed to assess the dynamics of prescription of monotherapy and PCT.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The greatest increase in the number of AHD was observed in patients with hypertension in combination with coronary heart disease, heart failure, and atrial fibrillation. In a small group of patients with hypertension without other CVDs, the recommended combinations of AHD were not prescribed; preference was given to angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and β-adrenoblocker (β-AB). PCT mainly differed from the recommended combinations by the wider use of drugs from the β-AB group. The PCT of recommended drugs was highest in patients with hypertension and coronary artery disease - more than 90%, hypertension and heart failure in 56.2%, hypertension and atrial fibrillation - 33.3%, hypertension and chronic kidney desease - 19.6%. Achievement of BP and low-density lipoprotein cholesterol targets was insufficient in all analyzed groups. Among the international nonproprietary names of drugs, the most frequently prescribed are the following: bisoprolol, metoprolol, lisinopril, perindopril, losartan, spironolactone, amlodipine, torasemide, indapamide, hypochlorothiazide, moxonidine. The prescribed daily dosages were closer to the initial recommended ones. By 2020, the prescription of PCT with β-AB and a more uniform prescription of various combinations will come to the fore, while PCT in 2010 is characterized by the presence of one ","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"96 9","pages":"860-871"},"PeriodicalIF":0.3,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142523178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Terapevticheskii Arkhiv
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1